Gilead Sciences Inc $89.33

up +0.47


22/7/2014 04:00 PM  |  NASDAQ : GILD  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get GILD Trend Analysis - it has outperformed the S&P 500 by 33%

Partner Headlines

  1. Earnings Scheduled For July 23, 2014

    Benzinga
  2. Alexion, 3 Other Top Biotechs Reporting Earnings

    IBD
  3. Biogen Shares Rebound As Street Has A Change Of Heart

    IBD
  4. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  5. Investors Focus On Earnings Rather Than Geopolitical Tensions

    Benzinga
  6. Biotech Enters Reporting Season With Large Caps Central To Sector Performance

    Benzinga
  7. Stocks Up In Late Trade; AerCap Nears Resistance

    IBD
  8. Stocks Add To Gains; Under Armour Rebounds

    IBD
  9. Yellen Swats Down Biotech, Social Media Stocks

    FoxBusiness
  10. J&J Earnings Beat Estimates, But Guidance Mixed

    IBD
  11. Economic News Today: Yellen Says Some Stock Valuations 'Stretched'

    IBD
  12. Biogen's Profit Rolls Amid Recent Drug Launches

    IBD
  13. Senate grills Gilead on price

    IBD
  14. Stocks Mixed In Low-Volume Session; Facebook Firms Up

    IBD
  15. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  16. Stocks Hitting 52-Week Highs

    Benzinga
  17. J.P. Morgan: Johnson & Johnson's Drug Segment May Beat Q2 Street Views

    Benzinga
  18. Alexion Pharma Looks To Life Beyond Its Blockbuster

    IBD
  19. Japan approves BMY regimen

    IBD
  20. Warmer Weather Improving Q2 Earnings Forecasts

    IBD
  21. Biotech Stocks Gilead, Anika Still Near Buy Points

    IBD
  22. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  23. Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics ...

    GuruFocus
  24. IBD 50: Salix, Gilead Among Top Expected EPS Gainers

    IBD
  25. Salix, Jazz Lead As Drugmakers Pace IBD 50 For Week

    IBD
  26. IBD 50: New Drug Driving Gilead's Sales, Earnings

    IBD
  27. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  28. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  29. Stocks Nearly Flat In Quiet Trading With 1 Hour To Go

    IBD
  30. Stocks Edge Higher In Soft Trade; Ambarella Adds To Gains

    IBD
  31. Stocks Up Slightly In Choppy Trade; BitAuto Rallies

    IBD
  32. UPDATE: Morgan Stanley Reiterates On Gilead Sciences On EM Sovaldi

    Benzinga
  33. Stocks Finish Higher; GoPro Extends IPO Advance

    IBD
  34. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  35. Vertex Cystic Fibrosis Success Quells Street's Doubts

    IBD
  36. Weekly CFO Sells Highlight: Facebook Inc, Workday Inc, Gilead Sciences ...

    GuruFocus
  37. Weekly Insider Sells Highlight: FB, NFLX, WDAY, GILD

    GuruFocus
  38. Achillion Could Win Idenix's Mystery Suitor: Analyst

    IBD
  39. Growing Insurer Centene Embraces Affordable Care Act

    IBD
  40. Advances In HIV, Hep C Treatments Could Spark Renewed Interest In Biotech ...

    Benzinga
  41. Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry

    IBD
  42. Achillion Gets Massive Price Target Hike On HCV Drugs

    IBD
  43. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  44. Achillion Gets Massive Price Target Hike On HCV Drugs

    IBD
  45. Julian Robertson Likes Uber, Google, Gilead, Stan Druckenmiller

    GuruFocus
  46. InterMune Up On Bullish View Of U.S. Esbriet Launch

    IBD
  47. Centene Dodges Bullets In Changing Medicaid Landscape

    IBD
  48. Sovaldi and Drug Pricing: The United States of Saps

    YCharts
  49. Achillion Forges Ahead With Hep C Program On FDA OK

    IBD
  50. Merck Makes Big Hep C Buy

    IBD
Trading Center